Next-Generation Antibody Market Report To 2028 By Top Key Players, Types & Applications

The global Next-Generation Antibody Market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.

The market for next-generation antibody therapeutics is growing due to rising incidence of cancer and increased demand. However, challenges in manufacturing and obtaining approvals hinder its growth.

Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00019765?utm_source=OpenPr&utm_medium=10640

Analysis of the Top Market Players:

1. F. HOFFMANN-LA ROCHE LTD.
2. Kyowa Kirin Co., Ltd.
3. Seagen Inc.
4. ImmunoGen, Inc.
5. Takeda Pharmaceutical Company Limited
6. Amgen Inc.
7. Pfizer Inc.
8. Catalent Inc
9. AstraZeneca
10. Xencor

In this report, the market has been segmented on the basis of:
Therapeutic Area (Oncology and Autoimmune or Inflammatory)
Technology (Antibody-Drug Conjugates, Bispecific Antibodies, Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins, and Biosimilar Antibody Products)

Get full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/next-generation-antibody-market

Next-generation antibodies are more specific and powerful than traditional monoclonal antibodies. These antibodies require advanced engineering to ensure stability, targeted delivery, and minimal off-target effects.

The next-generation antibody market is divided into therapeutic area, technology, and geography. By therapeutic area, the market is split into oncology and autoimmune/inflammatory, with the oncology segment having the larger share in 2021 and projected to have a higher growth rate. By technology, the next-generation antibody market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The antibody-drug conjugates segment is expected to dominate the market, while the bispecific antibodies segment is projected to have the highest growth rate due to increased usage in treating various diseases globally. The antibody-drug conjugates (ADCs) segment is anticipated to hold the largest share of the next-generation antibody market for several reasons. ADCs have emerged as a promising class of next-generation antibodies due to their ability to selectively deliver potent cytotoxic drugs to target cells.

Buy this research report at @: https://www.premiummarketinsights.com/buy/TIP00019765?utm_source=OpenPr&utm_medium=10640

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.